Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:CRBU NASDAQ:ELUT NASDAQ:HURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.77+17.4%$2.43$1.10▼$3.60$170.46M0.34643,416 shs850,611 shsCRBUCaribou Biosciences$1.77+5.4%$1.97$1.22▼$3.54$166.62M2.332.39 million shs2.80 million shsELUTElutia$0.96-4.3%$1.05$0.50▼$2.64$42.74M0.896,496 shs140,584 shsHURATuHURA Biosciences$2.29+6.0%$2.37$0.41▼$3.90$137.55M0.01702,192 shs793,665 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%+4.42%-9.23%+7.76%+110.71%CRBUCaribou Biosciences0.00%+2.75%-28.81%-2.33%+33.33%ELUTElutia0.00%-5.75%-13.88%-4.86%-52.43%HURATuHURA Biosciences0.00%-13.42%-1.55%+28.61%+0.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.77+17.4%$2.43$1.10▼$3.60$170.46M0.34643,416 shs850,611 shsCRBUCaribou Biosciences$1.77+5.4%$1.97$1.22▼$3.54$166.62M2.332.39 million shs2.80 million shsELUTElutia$0.96-4.3%$1.05$0.50▼$2.64$42.74M0.896,496 shs140,584 shsHURATuHURA Biosciences$2.29+6.0%$2.37$0.41▼$3.90$137.55M0.01702,192 shs793,665 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%+4.42%-9.23%+7.76%+110.71%CRBUCaribou Biosciences0.00%+2.75%-28.81%-2.33%+33.33%ELUTElutia0.00%-5.75%-13.88%-4.86%-52.43%HURATuHURA Biosciences0.00%-13.42%-1.55%+28.61%+0.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 2.33Hold$8.00188.81% UpsideCRBUCaribou Biosciences 2.75Moderate Buy$8.67389.64% UpsideELUTElutia 2.00Hold$6.00527.29% UpsideHURATuHURA Biosciences 2.67Moderate Buy$9.00293.01% UpsideCurrent Analyst Ratings BreakdownLatest ELUT, ABOS, CRBU, and HURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/11/2026CRBUCaribou Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.004/27/2026HURATuHURA Biosciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/27/2026HURATuHURA Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.004/21/2026HURATuHURA Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CRBUCaribou Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026HURATuHURA Biosciences Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/10/2026ELUTElutia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/8/2026ABOSAcumen Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026CRBUCaribou Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$1.16 per shareN/ACRBUCaribou Biosciences$11.16M15.73N/AN/A$1.31 per share1.35ELUTElutia$12.29M3.33N/AN/A$0.65 per share1.47HURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$121.33M-$1.86N/AN/AN/AN/A-123.07%-79.41%8/11/2026 (Estimated)CRBUCaribou Biosciences-$148.12M-$1.42N/AN/AN/A-1,189.14%-84.17%-60.51%8/11/2026 (Estimated)ELUTElutia$53.38M$0.861.11N/AN/A312.09%N/A-53.97%8/14/2026 (Estimated)HURATuHURA Biosciences-$30.05M-$0.61N/AN/AN/AN/A-156.12%-105.38%8/13/2026 (Estimated)Latest ELUT, ABOS, CRBU, and HURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026HURATuHURA Biosciences-$0.12-$0.13-$0.01-$0.13N/AN/A5/14/2026Q1 2026ELUTElutia-$0.15-$0.17-$0.02-$0.17$3.00 million$3.11 million5/12/2026Q1 2026ABOSAcumen Pharmaceuticals-$0.4028-$0.33+$0.0728-$0.33N/AN/A5/7/2026Q1 2026CRBUCaribou Biosciences-$0.33-$0.26+$0.07-$0.26$2.21 million$2.40 million3/31/2026Q4 2025HURATuHURA Biosciences-$0.1233-$0.13-$0.0067-$0.10N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.194.554.55CRBUCaribou BiosciencesN/A6.226.22ELUTElutiaN/A2.051.94HURATuHURA BiosciencesN/A1.151.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%CRBUCaribou Biosciences77.51%ELUTElutia74.03%HURATuHURA Biosciences0.62%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals10.20%CRBUCaribou Biosciences8.54%ELUTElutia27.60%HURATuHURA Biosciences0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2072.23 million64.86 millionOptionableCRBUCaribou Biosciences10099.18 million90.71 millionOptionableELUTElutia18042.78 million30.98 millionNot OptionableHURATuHURA BiosciencesN/A63.68 million63.56 millionN/AELUT, ABOS, CRBU, and HURA HeadlinesRecent News About These CompaniesTuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 29 at 4:15 AM | americanbankingnews.comTuHURA Biosciences, Inc.: TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets ...June 16, 2026 | finanznachrichten.deTuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood ...June 15, 2026 | finance.yahoo.comTuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related CancersJune 15, 2026 | prnewswire.comTuHURA Biosciences Draws on New $50M Credit FacilityMay 29, 2026 | tipranks.comHURA: Refining TBS-2025 development planMay 26, 2026 | msn.comTuHURA Biosciences, Inc.: TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateMay 16, 2026 | finanznachrichten.deTuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateMay 15, 2026 | prnewswire.comTuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor ConferenceMay 12, 2026 | prnewswire.comCitizens Initiates Coverage of TuHURA Biosciences (HURA) with Market Outperform RecommendationApril 28, 2026 | msn.comTuHURA Biosciences Secures $50 Million Credit FacilityApril 22, 2026 | tipranks.comTuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028April 22, 2026 | prnewswire.comWhy TuHURA Biosciences, Inc.’s (HURA) Stock Is Down 5.48%April 20, 2026 | aaii.comAIs TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?April 20, 2026 | finance.yahoo.comTuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical OperationsApril 7, 2026 | prnewswire.comTuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateApril 1, 2026 | prnewswire.comCraig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related CancersMarch 23, 2026 | prnewswire.comTuHURA Biosciences (NASDAQ:HURA) Trading Down 3.1% – Here’s WhyMarch 14, 2026 | defenseworld.netDTuHURA Biosciences, Inc.: TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price RequirementFebruary 27, 2026 | finanznachrichten.deTuHURA Biosciences stock gains after Nasdaq complianceFebruary 27, 2026 | za.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELUT, ABOS, CRBU, and HURA Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$2.77 +0.41 (+17.37%) Closing price 04:00 PM EasternExtended Trading$2.72 -0.06 (-1.99%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Caribou Biosciences NASDAQ:CRBU$1.77 +0.09 (+5.36%) Closing price 04:00 PM EasternExtended Trading$1.79 +0.02 (+1.13%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Elutia NASDAQ:ELUT$0.96 -0.04 (-4.25%) Closing price 04:00 PM EasternExtended Trading$0.96 +0.00 (+0.26%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.TuHURA Biosciences NASDAQ:HURA$2.29 +0.13 (+6.02%) Closing price 04:00 PM EasternExtended Trading$2.33 +0.04 (+1.70%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
